EN DE
Watch Sunny Pharmtech Inc. for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Sunny Pharmtech Inc. (6676) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of Sunny Pharmtech Inc. stock TWD 3.89, price TWD 6.98, that is 44.3% below the price, quality 34 out of 100. Rating: strongly overvalued. Calculated from audited financials with one of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare TW · ISIN TW0006676000

SP Sunny Pharmtech Inc. logo Thin data Nov 9, 2026

Sunny Pharmtech Inc.

6676 · TWO
Weakest Setup

Our calculation puts a fair price 44% below what the stock costs today.

Low debt
Mixed Growth (revenue 5y +12.3 %/yr in TWD)
Mixed vs. peers (4/10)
Revenue last quarter 19% below a year ago.
Fair value 3.89 TWD · Strongly overvalued
Quality 34/100
Loss-making · -139.3% net margin (TTM)
Negative free cash flow
Narrow moat 16/100
Thin data
Watch Sunny Pharmtech Inc. for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

18.50 TWD 6.98 TWD Fair Value 3.89 TWD Dec 2025 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 9, 2026.

How to read this chart

11‑month range 6.98 TWD – 18.50 TWD · fair‑value band 2.90 TWD – 5.81 TWD · the 6.98 TWD price screens above the 3.89 TWD fair value. As of Nov 9, 2026.

Follow Sunny Pharmtech in your weekly email

Every Wednesday you see whether Sunny Pharmtech is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Sunny Pharmtech Inc. engages in the research, development, and sale of new and generic drug in Taiwan, the United States, and internationally.

Show moreShow less

Its products portfolio include lidocaine ointment that can be used as an anesthetic lubricant for intubation, which temporarily relieves pain associated with minor burns, sunburn, skin abrasions, and insect bites; cyanocobalamin injection for use in vitamin B12 deficiency and pernicious anemia caused by malabsorption; nitrofurantoin capsules for urinary tract infection; aminocaproic acid tablets for blood diseases, as well as for hyper-proteolytic enzymes; and carboprost tromethamine injection for therapeutic abortion and postpartum hemorrhage, as well as Cyclophosphamide injection for malignant diseases.

The company was founded in 2014 and is based in Taoyuan City, Taiwan.

Stock analysis

Sunny Pharmtech Inc. (6676) currently trades at 6.98 TWD, while our model-based Fair Value estimate is 3.89 TWD, 44% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the data coverage at low.

Scenario range: 2.90 TWD (bear) to 5.81 TWD (bull), the price of 6.98 TWD sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 34/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Sunny Pharmtech Inc. reported revenue of 418M TWD in FY2024 versus 420M TWD in FY2020, a compound −0.1%/yr. Reported net income was −156M TWD in FY2024.

Key figures

Market cap 1.2B TWD (≈ $36.1M) Micro · P/S ratio 7.05 · EPS (TTM) −2.14 TWD · Net margin −139% · Return on equity −37.9% · Return on assets (EBIT) −8.4% (5-year average) · Operating margin −199% · Revenue (TTM) 233M TWD.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 16 out of 100 (medium confidence).

What moves the price

The share trades about 62% below its 52-week high and at its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −44%, 6676 screens richer than that median.

Fair Value models

Bear 2.90 TWD Fair Value 3.89 TWD Bull 5.81 TWD
Price 6.98 TWD · Downside -44.3%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
NCAV (Graham) 2.90 TWD 3.89 TWD 5.81 TWD 54
All 1 models by family
Asset-Based
NCAV (Graham) 2.90 TWD 3.89 TWD 5.81 TWD 54

Open the full fair value analysis →

Quality Score breakdown

Overall quality 34/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 7
How much profit the company makes from its sales and capital
Quality Growth 13
Are margins and returns getting better?
Cashflow 0
Do the profits arrive as real cash?
Financial strength 58
Debt, balance sheet and risk of trouble
Investment 82
Does it invest with discipline instead of growing at any price?
Low Volatility 64
How calm the share price moves, does not count
Price momentum 0
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 0
Distance to the 52-week high, does not count
New shares 69
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 26/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
−2.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+20.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+12.3%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−91.3% (2019) → −39.0% (2024)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2024 is a loss year, no rate is defined from a loss
not computed

6676 screens overvalued: fair value 44% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Sunny Pharmtech Inc. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 559 stocks

Beats the industry median on 4/9 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 34 · Below median
Fair Value upside −44.3% · Above median
Profitability
Return on assets −9.8% · Above median
Net margin (12 months) −139.3% · Bottom 25%
Operating margin (12 months) −199.5% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −18.6% · Bottom 25%
Balance sheet
Debt / equity 0.28× · Highest 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 1.13× · Cheapest 25%
P/S (12 months) 5.09× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)0 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)86 · sector 97
DIVIDEND (yield)0 · sector 22

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Incyte Corporation INCY $119.65 $199.23 +67% vs 6676
Regeneron Pharmaceuticals, Inc REGN $904.35 $1,275 +41% vs 6676
Genmab A/S GMAB kr 3,527 kr 3,999 +13% vs 6676
Vertex Pharmaceuticals Incorporated VRTX $547.09 $601.80 +10% vs 6676
Samsung Biologics Co 207940 1,516,000 KRW 1,667,600 KRW +10% vs 6676
WuXi Biologics (Cayman) Inc 2269 HK$47.62 HK$52.38 +10% vs 6676
argenx SE ARGX $927.21 $908.40 −2% vs 6676
CSL Limited CSL A$200.77 A$183.04 −9% vs 6676
Celltrion, Inc 068270 211,000 KRW 74,945 KRW −64% vs 6676
Royalty Pharma plc RPRX $67.30 $19.01 −72% vs 6676

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Sunny Pharmtech Inc.: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Sunny Pharmtech Inc. Fair Value". https://www.fairvalue-calculator.com/stock/6676

Frequently asked questions

Is Sunny Pharmtech Inc. (6676) overvalued or undervalued?
As of Nov 9, 2026, our model estimates a fair value of 3.89 TWD versus a price of 6.98 TWD, about 44% lower (overvalued).
What is the fair value of 6676?
Our model-based fair value for Sunny Pharmtech Inc. is 3.89 TWD (as of Nov 9, 2026), built from audited fundamentals. The current price: 6.98 TWD.
What is the quality score of 6676?
Sunny Pharmtech Inc. has a Quality Score of 34/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Sunny Pharmtech Inc. (6676)?
Our model-based price target is the fair value of 3.89 TWD (as of Nov 9, 2026) from 1 valuation models. Cautious scenario 2.90 TWD, optimistic scenario 5.81 TWD. It is a calculation from audited fundamentals, not an analyst target.
What is the Sunny Pharmtech Inc. stock forecast for 2026?
Our models put fair value at 3.89 TWD, about 44% lower versus a price of 6.98 TWD (overvalued). Cautious scenario 2.90 TWD, optimistic scenario 5.81 TWD. The calculation is refreshed regularly with new filings.
What is the revenue of Sunny Pharmtech Inc. (6676)?
Sunny Pharmtech Inc. reported trailing-twelve-month revenue of about 233M TWD (latest available figure, as of Nov 9, 2026).
What is the intrinsic value of Sunny Pharmtech Inc. (6676)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Sunny Pharmtech Inc. it is 3.89 TWD per share (as of Nov 9, 2026), against a price of 6.98 TWD. It is the blended result of 1 valuation models in 1 family (Asset-Based).
Is Sunny Pharmtech Inc. stock overvalued or undervalued in 2026?
As of Nov 9, 2026, 6676 trades above its calculated fair value: price 6.98 TWD, fair value 3.89 TWD, a gap of about −44% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 6676?
No. The price is what the market pays today (6.98 TWD); the fair value is what the company's own numbers justify (3.89 TWD). For Sunny Pharmtech Inc. the two are 3.09 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is Sunny Pharmtech Inc. worth?
The market values Sunny Pharmtech Inc. at about 1.2B TWD (market capitalisation, as of Nov 9, 2026). Per share that is 6.98 TWD; our models calculate a fair value of 3.89 TWD per share.
What do the bullish and bearish scenarios say about 6676?
Our models span a range for Sunny Pharmtech Inc.: cautious scenario 2.90 TWD, base 3.89 TWD, optimistic 5.81 TWD per share (as of Nov 9, 2026, price 6.98 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Sunny Pharmtech Inc. (6676)?
Balance-sheet figures for Sunny Pharmtech Inc. (as of Nov 9, 2026): return on equity −37.9%, debt of 0.28 per unit of equity. They feed the Quality Score of 34/100, which measures business quality independently of the share price.
How far is 6676 from its 52-week high?
Sunny Pharmtech Inc. trades at 6.98 TWD, about 62% below its 52-week high of 18.50 TWD and at the low of 6.98 TWD (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of 3.89 TWD is for.
Which stocks are comparable to Sunny Pharmtech Inc.?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Sunny Pharmtech Inc. stock attractive at the current price?
The data as of Nov 9, 2026: price 6.98 TWD, calculated fair value 3.89 TWD (−44%), Quality Score 34/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 6676 calculated?
We run Sunny Pharmtech Inc. through 1 models from 1 family: Asset-Based. Every model gets the same audited fundamentals; the fair value of 3.89 TWD builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Sunny Pharmtech Inc. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Sunny Pharmtech Inc. (6676)?
The closing price on Nov 6, 2026 was 6.98 TWD. Our model-based fair value is 3.89 TWD, about 44% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Sunny Pharmtech Inc. right now?
The price sits above even our optimistic bull case (5.81 TWD). The favourable scenario is already priced in. Weak quality (34/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (2.90 TWD to 5.81 TWD) leaves room in how you read the outcome.

Key figures of Sunny Pharmtech Inc.

How large is the market capitalisation of Sunny Pharmtech Inc. (6676)?
The market capitalisation of Sunny Pharmtech Inc. is 1.2B TWD (≈ $36.1M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Sunny Pharmtech Inc. (6676)?
The price-to-sales ratio of Sunny Pharmtech Inc. is 7.05 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Sunny Pharmtech Inc. (6676)?
Earnings per share at Sunny Pharmtech Inc. are −2.14 TWD. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Sunny Pharmtech Inc. (6676)?
The net margin of Sunny Pharmtech Inc. is −139% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Sunny Pharmtech Inc. (6676)?
The return on equity (ROE) of Sunny Pharmtech Inc. is −37.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Sunny Pharmtech Inc. (6676)?
On an EBIT basis the return on assets of Sunny Pharmtech Inc. is −8.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Sunny Pharmtech Inc. (6676)?
The operating margin of Sunny Pharmtech Inc. is −199% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Sunny Pharmtech Inc. (6676)?
Revenue at Sunny Pharmtech Inc. is growing −18.6% versus a year earlier (3y avg +20.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Sunny Pharmtech Inc. (6676) generate?
The free cash flow of Sunny Pharmtech Inc. is −86.6M TWD (fiscal year 2024). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Sunny Pharmtech Inc. (6676) carry?
The net debt of Sunny Pharmtech Inc. is 248M TWD (fiscal year 2024). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Sunny Pharmtech Inc. in the live analysis

One click puts Sunny Pharmtech Inc. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.